“Biote’s third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to growth in our dietary supplements business,” said ...

Reports Q3 revenue $51.4M, consensus $51.4M. “Biote’s (BTMD) third quarter revenue increased 12.8% from the prior-quarter period, driven by continued growth in procedure revenue and a strong return to ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

Peterson stated, "we reiterate our fiscal 2025 revenue guidance of above $190 million and our fiscal 2025 adjusted EBITDA guidance of above $50 million." Management continues to expect mid-teens ...

Reports Q4 revenue $49.8M, consensus $51.2M. “In 2024 Biote (BTMD) strengthened its capabilities to provide the next level of individualized and evidence-based healthcare,” said Bob Peterson, Biote ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated medical practice-building business within the hormone optimization space, today ...

biote Corp. beats earnings expectations. Reported EPS is $0.18, expectations were $0.08. biote Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the ...

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today ...